Polyrizon Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Clinical Trial Sites Secured for NASARIX™ (PL-14) Allergy Blocker Trial Quarterly3.0Target: Initiation of multi-center human clinical trial
Cash and Cash Equivalents (including bank deposits) Quarterly17.5MTarget: Sufficient liquidity to fund near-term clinical and regulatory milestones
Watch Items
- FDA Regulatory Pathway for PL-16 Viral BlockerTrigger: FDA response to Pre-Request for Designation (Pre-RFD) submitted in December 2025Action: Determine OTC status and finalize clinical/regulatory requirements for PL-16
- NASARIX™ (PL-14) First-in-Human Clinical Trial ProgressTrigger: First patient enrolled in the seasonal allergic rhinitis studyAction: Evaluate safety, tolerability, and efficacy compared to saline spray
- Strategic Investment in Colugo SystemsTrigger: Execution of definitive agreement under the non-binding MOU for up to 20% stakeAction: Assess capital allocation impact and integration of eVTOL drone technology exposure
Research as of 20 Jun 2026